塞利尼索(Selinexor) - 药物靶点：XPO1_在研适应症：浆细胞骨髓瘤难治，复发性多发性骨髓瘤，复发性弥漫性大B细胞淋巴瘤_专利_临床

This phase II trial compares the combination of selinexor, daratumumab, Velcade (bortezomib), and dexamethasone (Dara-SVD) to the usual treatment of daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVD) in treating patients with high-risk newly diagnosed multiple myeloma. Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The drugs daratumumab, lenalidomide, bortezomib, dexamethasone and selinexor are already approved by the FDA for use in myeloma. But selinexor is not used until myeloma comes back (relapses) after initial treatment. Giving selinexor in the initial treatment may be a superior type of treatment for patients with high-risk newly diagnosed multiple myeloma.

开始日期2024-11-16

申办/合作机构

National Cancer Institute

NCT06452446 / Not yet recruitingN/A

Telehealth-based Symptom Management for Veterans Treated With Selinexor

The purpose of this study is to find out if continued monitoring of side effects from Selinexor and prescribed medication to prevent side effects helps improve symptoms, quality of life, and ability to continue the treatment longer.

开始日期2024-07-01

申办/合作机构

Durham VA Medical Center

[+1]

NCT06158841 / Recruiting临床3期

A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of ABBV-383 compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM.
ABBV-383 is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. . In Arm A, participants will receive ABBV-383 as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world.
In Arm A participants will receive ABBV-383 as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable, during the 3.5 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

开始日期2024-05-09

申办/合作机构

AbbVie, Inc.

100 项与塞利尼索相关的临床结果

登录后查看更多信息

100 项与塞利尼索相关的转化医学

登录后查看更多信息

100 项与塞利尼索相关的专利（医药）

登录后查看更多信息

438

项与塞利尼索相关的文献（医药）

2024-03-01·Cancer chemotherapy and pharmacology

Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/β-catenin signaling pathway in breast cancer

Article

作者: Shi, Yingfang ; Xu, Shengxi ; Li, Sen

BACKGROUND:

The intricate relationship between Forkhead box O1 (FOXO1), a well-established tumor suppressor, and breast cancer (BC) remains partially elucidated. This study aims to investigate the mechanistic role of FOXO1 nuclear localization in the context of BC.

METHODS:

In vitro experiments employed BC cell lines MCF-7 and MDA-MB-175 treated with LOM612, a small molecule activator of FOXO nuclear-cytoplasmic shuttling, and selinexor, an exportin 1 inhibitor. Nuclear accumulation of FOXO1, its interaction with β-catenin, and expressions of key proteins like V-Myc avian myelocytomatosis viral oncogene homolog (c-Myc), cyclin D1 and apoptosis markers were assessed. In vivo, the effects of LOM612 and selinexor were studied using MCF-7 cell-derived xenografts (CDX).

RESULTS:

Treatment with LOM612 exhibited a significant enhancement in nuclear accumulation of FOXO1 within BC cells. This effect coincided with suppressed migratory behavior and heightened apoptosis susceptibility in these cells. Mechanistically, LOM612 orchestrated FOXO1 to compete with transcription factors (TCF) for binding to β-catenin in the nucleus, leading to reduced c-Myc and cyclin D1 expressions, along with elevated levels of apoptosis-related proteins. Similar trends were observed in CDX models, where LOM612 effectively suppressed tumor growth, increased FOXO1 nuclear localization, and downregulated c-Myc and cyclin D1 expressions. Importantly, selinexor synergistically reinforced the therapeutic effects of LOM612 both in vitro and in vivo.

CONCLUSIONS:

Collectively, this study underscores the potential of combining LOM612 and selinexor as an efficacious anti-BC strategy. The underlying mechanism involves FOXO1's nuclear translocation, which disrupts TCF-β-catenin interactions, thus indirectly inhibiting the Wnt/β-catenin signaling pathway.

2024-02-01·American journal of hematology

Two p53s in a Pod: Co‐occurring plasma cell myeloma and therapy‐related myeloid neoplasm following lenalidomide therapy

作者: Monge, Jorge ; Bao, Liming ; Patel, Sanjay S. ; Razavi, Meri

A case of 78-yr-old man with relapsed/refractory IgG-kappa multiple myeloma was electively admitted to the hospital for teclistamab step-up therapy is reported.He had received four prior lines of therapy: bortezomib/lenalidomide/dexamethasone, lenalidomide, daratumumab/ carfilzomib/pomalidomide/dexamethasone, bortezomib/selinexor/dexa- methasone; requiring multiple dose reductions for cytopenias.Fluorescence in situ hybridization detected heterozygous TP53 deletion in myeloma (CD138+) and non-myeloma (CD138) cell fractions.

2024-02-01·Expert opinion on drug safety

Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase)

Article

作者: Zheng, Yi ; Guo, Xiaojing ; Liang, Jizhou ; Chi, Lijie ; Chen, Chenxin ; Miao, Xiaoyong ; Wei, Lianhui ; He, Jia ; Xu, Jinfang ; Ye, Xiaofei ; Zhang, Hewei ; Chen, Xiao

BACKGROUND:

Exportin 1 (XPO1) inhibitors are being developed as a new agent for anti-cancer therapies. This study aimed to broadly portray the adverse event (AE) profile of selinexor, an XPO1 inhibitor, in actual clinical practice.

RESEARCH DESIGN AND METHODS:

Disproportionality analyses were conducted by calculating the information component and reporting odds ratio in VigiBase over different reporting periods. All selinexor-related AEs were classified by system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities.

RESULTS:

A total of 116,443 AEs were identified in 2,608 patients that received selinexor. Patients with cardiac disorders had a higher propensity for death. Thirteen SOCs and 125 PTs were identified as having a potential connection with selinexor. Notably, 29 suspected signals detected in our study were defined as significant AEs by the European Medicines Agency, including febrile neutropenia, pancytopenia, and acute kidney injury. Attention should be paid to these AEs, despite most toxicities being manageable and reversible.

CONCLUSIONS:

This study highlights a number of AEs associated with selinexor. Most toxicities are reversible but require careful management. The benefit of selinexor still outweighs the potential risks, indicating XPO1 inhibitors as promising agents.

357

项与塞利尼索相关的新闻（医药）

2024-07-01

·BioSpace

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2024

NEWTON, Mass., July 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 8,800 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of June 30, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the applicable RSU agreement). About Karyopharm Therapeutics Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of exU.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm. XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. View original content to download multimedia: SOURCE Karyopharm Therapeutics Inc. Company Codes: NASDAQ-NMS:KPTI

上市批准临床结果快速通道加速审批

2024-06-27

·GBIHealth

逾8亿美元减值损失！诺和诺德终止肾病药物III期试验

药械追踪 No.1 / 百奥泰托珠单抗获欧盟委员会批准上市 2024年6月26 日，百奥泰（688177.SH）发布公告称，合作伙伴渤健于近日收到欧盟委员会通知，TOFIDENCE（BAT1806，托珠单抗注射液）获得欧盟委员会上市批准，用于治疗类风湿性关节炎、多关节型幼年特发性关节炎、全身型幼年特发性关节炎和COVID-19。 BAT1806是百奥泰根据中国国家药品监督管理局（NMPA）、美国食品药品监督管理局（FDA）、欧洲药品管理局（EMA）生物类似药相关指导原则开发的托珠单抗注射液。百奥泰与Biogen于2021年4月签署授权许可与商业化协议，将公司的BAT1806（托珠单抗注射液）在除中国地区（包括中国大陆、中国香港特别行政区、中国澳门特别行政区、中国台湾地区）以外的全球市场的独占的产品权益有偿许可给渤健。 ->点击阅读原文，解锁完整双语新闻 No.2 / 德琪医药希维奥在韩国批准纳入医保 2024年6月26日，德琪医药（6996.HK）宣布，韩国国民健康保险公团（NHIS）批准希维奥（塞利尼索片）纳入医保，用于治疗复发/难治性多发性骨髓瘤（R/R MM）成人患者。希维奥将于2024年7月1日起正式纳入韩国医保报销药品目录。塞利尼索是全球首创选择性核输出（SINE）抑制剂药物，由Karyopharm Therapeutics Inc.（NSDQ：KPTI）开发。德琪医药引入塞利尼索后，首个获批国家为韩国。2021年12月，塞利尼索获国家药监局附条件批准上市，2022-2023年陆续在中国台湾、香港、澳门获批上市。此次获批进入韩国医保，是继中国大陆、澳大利亚和新加坡之后，公司在第四个亚太地区市场实现对于希维奥的医保覆盖。 ->点击阅读原文，解锁完整双语新闻企业动态 No.1 / 诺和诺德终止肾病药物III期试验，预计录得逾8亿美元减值损失诺和诺德（NYSE:NVO；CPH:Novo-B）近日宣布，其在研药物ocedurenone用于治疗慢性肾脏疾病（CKD）的III期CLARION-CKD研究未能达到主要终点。该公司已决定停止CKD的临床试验，不过仍在考虑是否继续其它适应证的试验。根据新闻稿，诺和诺德将在2024年第二季度计入约57亿丹麦克朗（约合8.1672亿美元）的减值损失，相当于2024年的营业利润将下降6个百分点。诺和诺德于2023年10月与新加坡公司KBP Bioscience达成协议，以最高不超过13亿美元的总金额收购了ocedurenone，当时该药物已经在进行CLARION-CKD试验。在达成协议时，诺和诺德表示计划启动该药用于治疗心血管疾病和其它肾脏疾病的III期临床试验；但现在，该公司称，“目前正在评估”ocedurenone针对其它适应证的进一步开发。 ->点击阅读原文，解锁完整双语新闻 No.2 / 拓济医药完成超亿元Pre-A轮融资，致力领跑ADC领域近日，国内领先的双抗ADC公司拓济医药（Phrontline Biopharma）宣布完成超亿元Pre-A轮融资，由德诚资本独家投资，指数资本担任独家财务顾问。本轮融资后，拓济将加大研发投入力度，加快多个临床前管线推进，升级自有技术平台。拓济医药成立于2022年初，做源头创新的ADC药物。其自主技术平台涵盖了ADC药物四项核心技术（毒素、连接子、偶联方式、抗体），快速建立了先进的抗体发现和双抗制备平台，Linker-Payload设计合成平台，定点定量偶联技术平台等。 ->点击阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I ” 自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作 ▶ zhangxinyue13@baidu.com 数据库 | 咨询服务 | 资讯追踪 ▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

上市批准临床3期并购生物类似药

2024-06-26

·药时代

德琪医药希维奥®在韩国获得医保批准，改善多发性骨髓瘤患者治疗选择

希维奥®是首款获韩国国民健康保险公团（NHIS）批准纳入医保，用于治疗复发/难治性多发性骨髓瘤（R/R MM）成人患者的XPO1抑制剂。这是继中国大陆、澳大利亚和新加坡之后，公司在第四个亚太地区市场实现对于希维奥®的国家医保覆盖。公司预计希维奥®将在亚太地区的更多国家获得医保收录。公司已在包含泰国、马来西亚和印度尼西亚在内的多个东盟国家提交了希维奥®的新药上市申请（NDA），这些申请预计将于2024年下半年获得批准。中国上海和香港，2024年6月26日–致力于研发，生产和销售同类首款及/或同类最优血液及实体肿瘤疗法的商业化阶段领先创新生物制药公司–德琪医药有限公司（简称“德琪医药”，香港交易所股票代码：6996.HK）今日宣布，韩国国民健康保险公团（NHIS）批准希维奥®（塞利尼索片）纳入医保，用于治疗复发/难治性多发性骨髓瘤（R/R MM）成人患者。希维奥®将于2024年7月1日起正式纳入韩国医保报销药品目录。多发性骨髓瘤（MM）是一种克隆浆细胞异常增殖导致的恶性疾病，是血液系统第二大常见恶性肿瘤。多数患者都面临着易复发、生存期短、治疗选择有限的困境。根据市场研究报告，2023年全球多发性骨髓瘤治疗市场规模已超过170亿美元，并预计在2028年达到260亿美元，年均复合增长率（CAGR）为8.7%[1]。希维奥®是全球首个全新机制的口服选择性XPO1抑制剂，已在全球40多个国家和地区获批上市。截至目前，希维奥®已在中国大陆、澳大利亚和新加坡这几个亚太地区市场实现医保收录。此次希维奥®成功获得韩国NHIS医保报销批准，将为更多患者带来全新的创新治疗选择和具有临床意义的生存获益。公司已在泰国、马来西亚、印度尼西亚递交希维奥®的新药上市申请，用于治疗R/R MM及弥漫性大B细胞淋巴瘤（R/R DLBCL）。关于希维奥®（塞利尼索）希维奥®是全球首个全新机制的口服选择性核输出蛋白（XPO1）抑制剂，具有“全新机制、协同增效、快速起效、持久缓解”四大特点。通过抑制核输出蛋白XPO1，希维奥®可促使肿瘤抑制蛋白和其他生长调节蛋白的核内储留和活化，并下调细胞浆内多种致癌蛋白水平。希维奥®发挥抗肿瘤作用机制的三条通路为：1）使抑癌蛋白在细胞核中明显聚集，再激活发挥抗肿瘤作用；2）使致癌基因mRNA滞留在细胞核，降低胞浆内致癌蛋白水平；3）激活糖皮质激素受体（GR）通路，恢复激素敏感性。基于其独特的作用机制，希维奥®在不同疾病领域的多种联合疗法正在进行开发。目前，德琪医药正在中国大陆地区开展多项（其中三项全球临床试验由德琪医药与Karyopharm Therapeutics Inc.[纳斯达克交易所股票代码：KPTI] 共同开展）针对复发/难治性血液及实体肿瘤的临床研究。关于德琪医药德琪医药有限公司（简称“德琪医药”，香港交易所股票代码：6996.HK）是一家以研发为驱动，并已进入商业化阶段的生物制药领先企业，以“医者无疆，创新永续”为愿景，德琪医药专注于血液及实体肿瘤领域的同类首款和同类最优疗法的早期研发、临床研究、药物生产及商业化，致力于通过提供突破性疗法，改善全球患者生活质量。自2017年以来，德琪医药现已建立起一条拥有9款从临床延展至商业化阶段的肿瘤药物资产研发管线，其中，6款产品具有全球权益，3款产品具有亚太权益。公司已在美国及多个亚太市场获得29个临床批件（IND），并递交了10个新药上市申请（NDA）。目前，希维奥®（塞利尼索片）已获得中国大陆、中国台湾、中国香港、中国澳门、韩国、新加坡和澳大利亚的新药上市批准。前瞻性陈述本文所作出的前瞻性陈述仅与本文作出该陈述当日的事件或资料有关。除法律规定外，于作出前瞻性陈述当日之后，无论是否出现新资料、未来事件或其他情况，我们并无责任更新或公开修改任何前瞻性陈述及预料之外的事件。请细阅本文，并理解我们的实际未来业绩或表现可能与预期有重大差异。本文内有关任何董事或本公司意向的陈述或提述乃于本文刊发日期作出。任何该等意向均可能因未来发展而出现变动。有关这些因素和其他可能导致未来业绩与任何前瞻性声明存在重大差异的因素的进一步讨论，请参阅我们截至2023年12月31日的公司年报中描述的其他风险和不确定性，以及之后向香港证券交易所提交的文件。参考文献： 1.Global Multiple Myeloma Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Stem Cell Transplantation), by Region, and Segment Forecasts, 2023-2028 点击这里，更多了解德琪医药！

信使RNA上市批准申请上市

100 项与塞利尼索相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11222	-	L01XX66	DB11942

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
浆细胞骨髓瘤难治	中国澳门	德琪医药有限公司	2023-12-06
复发性多发性骨髓瘤	中国澳门	德琪医药有限公司	2023-12-06
复发性弥漫性大B细胞淋巴瘤	以色列	Karyopharm Therapeutics, Inc.	2021-02-04
难治性弥漫性大 B 细胞淋巴瘤	以色列	Karyopharm Therapeutics, Inc.	2021-02-04
弥漫性大B细胞淋巴瘤	美国	Karyopharm Therapeutics, Inc.	2020-06-22
多发性骨髓瘤	美国	Karyopharm Therapeutics, Inc.	2019-07-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性急性髓细胞白血病	临床3期	中国	德琪医药有限公司	2023-01-29
复发性急性髓细胞白血病	临床3期	中国	德琪医药有限公司	2023-01-29
子宫内膜癌	临床3期	中国	Karyopharm Therapeutics, Inc.	2021-10-27
子宫内膜癌	临床3期	中国	德琪医药有限公司	2021-10-27
骨髓纤维化	临床3期	美国	Karyopharm Therapeutics, Inc.	2021-03-11
骨髓纤维化	临床3期	比利时	Karyopharm Therapeutics, Inc.	2021-03-11
骨髓纤维化	临床3期	保加利亚	Karyopharm Therapeutics, Inc.	2021-03-11
骨髓纤维化	临床3期	加拿大	Karyopharm Therapeutics, Inc.	2021-03-11
骨髓纤维化	临床3期	捷克	Karyopharm Therapeutics, Inc.	2021-03-11
骨髓纤维化	临床3期	丹麦	Karyopharm Therapeutics, Inc.	2021-03-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04425070 (TOUCH, ASCO2024) 人工标引	临床1/2期	结外NK-T细胞淋巴瘤	12	Selinexor+tislelizumab	蓋遞觸願餘鹽壓壓選簾(構糧鏇鏇構積鏇簾膚觸) = 廠遞製壓遞繭鏇壓窪醖遞鹹選製簾鹹繭廠淵遞 (艱糧夢齋選觸鏇膚齋製 ) 更多	积极	2024-05-24
NCT05980806 (XPORT-MF-044, ASCO2024)	临床2期	血小板减少症 \| 骨髓纤维化 JAKi-naïve \| moderate thrombocytopenia	-	Selinexor 40 mg	遞鏇夢網構獵繭願繭蓋(襯糧夢構鹽觸膚齋鏇鏇) = 艱廠夢獵夢膚齋齋淵積壓夢願醖製獵選窪醖艱 (淵鹹鹽夢鹽齋鬱夢襯選 ) 更多	积极	2024-05-24
NCT05980806 (XPORT-MF-044, ASCO2024)	临床2期	血小板减少症 \| 骨髓纤维化 JAKi-naïve \| moderate thrombocytopenia	-	Selinexor 60 mg	遞鏇夢網構獵繭願繭蓋(襯糧夢構鹽觸膚齋鏇鏇) = 獵製壓築夢網蓋鬱積鏇壓夢願醖製獵選窪醖艱 (淵鹹鹽夢鹽齋鬱夢襯選 ) 更多	积极	2024-05-24
NCT03193437 \| NCT03466827 (phase II, ASCO2024)	临床2期	胸腺瘤 \| 胸腺癌	31	Selinexor 60 mg	鏇醖範簾獵鏇遞築觸鹽(衊顧選觸醖餘醖範壓餘) = 齋觸鹽鬱築鑰鏇餘艱憲製築衊鏇簾艱膚壓繭網 (築鏇醖夢願蓋淵夢醖顧, 1.2 ~ 29.8) 更多	不佳	2024-05-24
NCT03193437 \| NCT03466827 (phase II, ASCO2024)	临床2期	胸腺瘤 \| 胸腺癌	31	Selinexor 40 mg	鏇醖範簾獵鏇遞築觸鹽(衊顧選觸醖餘醖範壓餘) = 淵膚顧衊構築夢簾遞窪製築衊鏇簾艱膚壓繭網 (築鏇醖夢願蓋淵夢醖顧, 3.5 ~ 36.0) 更多	不佳	2024-05-24
NCT03095612 (ASCO2024)	临床1/2期	KRAS突变非小细胞肺癌	40	Selinexor	獵醖糧淵窪窪糧繭選獵(鬱糧醖鬱憲淵醖鏇衊遞) = 50%, Gr ≥3 0% 壓醖艱鑰觸憲鹹鏇齋襯 (鹹廠觸繭築醖獵糧齋築 ) 更多	积极	2024-05-24
NCT04562389 (XPORT-MF-034, ASCO2024)	临床3期	骨髓纤维化 JAK2 \| CALR \| MPL	306	Selinexor 60 mg	糧鹹鹹鑰醖願齋衊襯選(憲窪築鏇願網齋夢餘選) = 夢鏇憲壓繭鬱網顧築艱觸淵襯築簾壓顧糧衊願 (窪憲蓋膚構鹹鹽憲鬱築 ) 更多	积极	2024-05-24
NCT02343042 (STOMP, EHA2024) 人工标引	临床1/2期	多发性骨髓瘤	21	Selinexor + ixazomib + dexamethasone (SNd)	製選壓鏇鑰廠窪願壓窪(糧壓鹹鹽遞願願窪製顧) = 選憲繭衊製願願餘糧醖淵遞構齋築顧襯鏇築淵 (餘膚憲築衊積壓艱淵艱 )	积极	2024-05-14
NCT02343042 (STOMP, EHA2024) 人工标引	临床1/2期	多发性骨髓瘤	21	Selinexor + pomalidomide + elotuzumab + dexamethasone (SPEd)	製選壓鏇鑰廠窪願壓窪(糧壓鹹鹽遞願願窪製顧) = 獵憲簾遞衊構繭鑰鏇選淵遞構齋築顧襯鏇築淵 (餘膚憲築衊積壓艱淵艱 )	积极	2024-05-14
NCT05951855 (EHA2024) 人工标引	临床2期	急性髓性白血病	11	SELINEXOR+CHIDAMIDE	醖繭製築繭襯築膚製淵(廠膚鬱淵獵廠觸鹹顧願) = 餘獵範鹹艱獵鑰淵製顧鹽窪醖壓艱廠構構鏇廠 (齋膚鹽鬱鑰窪獵鹹齋餘 ) 更多	积极	2024-05-14
EHA2024	临床1/2期	-	9	Selinexor 40mg	鏇簾選選顧築鏇艱願選(簾鬱壓齋膚醖觸艱顧觸) = 顧鹽夢鹽鬱醖艱鹹製範範觸範齋製範製艱廠壓 (膚憲襯齋觸壓餘簾鑰積 ) 更多	积极	2024-05-14
NCT04425070 (TOUCH, EHA2024)	临床1/2期	结外NK-T细胞淋巴瘤 L-Aspariginase \| PD-1 antibody \| PD-L1 antibodies ... 更多	12	Selinexor 40mg	壓衊鬱願襯積鏇蓋觸衊(製選網齋醖齋廠齋壓遞) = The most common TEAEs were asthenia (83.3%), neutropenia (83.3%), nausea/vomiting (58.3%), decreased appetite, weight loss, anemia, thrombocytopenia (50.0%, respectively), lymphocytopenia (41.7%), pneumonia, AST increased and proteinuria (33.3%, respectively) 夢夢艱廠膚構襯鑰鑰醖 (網餘網遞鏇範鏇築鏇夢 ) 更多	积极	2024-05-14
NCT04425070 (TOUCH, EHA2024)	临床1/2期		12	Selinexor 60mg		积极	2024-05-14
NCT04562389 (XPORT-MF-034, EHA2024)	临床3期	骨髓纤维化 JAK2 \| CALR \| MPL	306	Selinexor 60 mg QW + Ruxolitinib	積鏇壓膚糧願鬱蓋窪衊(鏇鏇鹹鑰壓鑰鏇觸窪衊) = 鹽獵鏇鏇鬱衊鑰糧願鏇積鏇遞顧鬱糧衊衊繭衊 (繭夢鑰顧選窪衊壓顧衊 ) 更多	积极	2024-05-14